TriLink Opens GMP Enzyme Facility to Support RNA Therapeutic Manufacturing

TriLink, part of Maravai LifeSciences , announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production.

The Jupiter facility was purpose-built for GMP enzyme manufacturing. It features controlled cleanroom environments, validated production processes, and scalable capacity designed to support both clinical-stage programs and commercial supply. Full traceability and quality systems are in place to meet regulatory requirements across major markets.

The facility is already supporting customer programs, with TriLink successfully shipping its first commercial GMP enzyme batch in June 2026. This milestone demonstrates the facility’s operational readiness and ability to provide commercial-scale supply of critical IVT raw materials to RNA therapeutics developers worldwide.